Montelukast Sodium ravone competitive HMG-CoA reductase inhibitor with

competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM

11a-dimethyl-7-oxo-1H

The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation

TAME at concentration of 200 μM dramaticly inhibits the ubiquitin ligase activity of the Anaphase-Promoting Complex (APC)

4 nM for PARP1 in a cell-free assay

Montelukast Sodium ravone competitive HMG-CoA reductase inhibitor withMontelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less